Artificial Intelligence for Repurposing of Drugs


Although advances have been taking place in the pharmaceutical industry over the past years, the development of new drugs even takes about ~15 years and 800 million to one billion dollars. To cope with this problem, drug repurposing is a newly emerging technique in which existing drugs treat various other diseases. It has been a promising approach because of the opportunity for reduced development timelines and overall costs. It maximizes the potential usage of the existing drugs and increases the number of new drugs. It is a low-cost method of repurposing medications for new medical purposes.

In the past few years, various computational approaches have been used in drug repurposing, such as in-silico drug repurposing. Several articles are present in which there is a discussion of how computational methods such as artificial intelligence (AI) and Machine learning (ML) based on network propagation, matrix factorization, and completion are used. So here, Artificial intelligence (AI) and many computational methods accelerate drug repurposing.

Several machine learning (ML) and artificial intelligence (AI) algorithms have been developed to discover drug repurposing systematically leads using big data resources, thereby speeding up the drug development process.

For the complete in-depth article on ‘Artificial Intelligence for Drug Repurposing’, please visit @ https://www.iebrain.com/artificial-intelligence-for-repurposing-of-drugs/

About Ingenious e-Brain Solutions: -

Ingenious e-Brain Solutions provides high-quality, customized, and cost-effective Technology Intelligence, Business Intelligence, and Intellectual Property Intelligence solutions to industry leaders, and innovative companies across the globe. Innovation, knowledge, and transparency form the basis of our company’s mission and vision. Along with cost benefits, we provide highest quality results ensuring fool-proof confidentiality and security. We are an ISO certified company with offices in India and USA.

Ingenious e-Brain Solutions has a strong team of analysts, and subject matter experts with domain proficiency which is devoted to help clients grow. Our highly qualified professionals offer tailored, value-added and cost-effective services to our clients. We believe in building long term relationships with our clients who include national and international corporations, Fortune 500 companies, world’s leading research institutes and universities as well as independent inventors.

Get in Touch: -
India Office
207-208 Welldone TechPark, Sohna Road
Sector 48, Gurugram, Haryana 122018, India
+91 124 429 4218

Email: -
queries@iebrain.com

Comments

Post a Comment

Popular posts from this blog

Hybrid Meat Analogues – A Middle Ground between Plant-based & Traditional Meat

Image
I n the context of semi-vegetarian choices, hybrid meat analogues are emerging as an alternative to traditional meat products. These are produced using blends of plant and animal ingredients in varying proportions to provide a meaty taste and texture, with the added nutritional benefits from plants. Compared to plant-based alternatives, hybrid analogues such as burgers, sausages, meatballs, and mince have the potential to reduce GHG emissions by 32% if 50% of meat is replaced by plant proteins. The development of hybrid meat analogues begets opportunities and challenges due to the alterations in technical & sensory properties (texture, appearance, taste, etc.) of the meat matrices caused by plant portion. Technical challenges Major technical challenge faced while blending plant-based proteins with meat proteins is the formation of elastic gels through the enclosure of water and fat particles in the protein network upon heating due to the high emulsifying capacity of myofibrilla...
Read more

IEBS Broadening its Horizons Digitally by Allying with Scientist.com as a Registered Supplier

Image
It is a moment of pride for Ingenious e-Brain Solutions (IEBS) that it has become an affiliated supplier of Scientist.com¬—a renowned digital healthcare research platform. Artificial Intelligence (AI) and digitalization are transcending all technologies and have revolutionized how industries operate. Therefore, IEBS has attempted to grow its digital presence by registering with Scientist.com. As the latter is solely a healthcare domain platform, we offer one element from our extensive list of business consulting solutions at Scientist.com. Here, we deliver healthcare-related latest technological & real-time business insights, emphasize potential opportunities for business propulsion, and provide innovative & strategic enterprise solutions on this platform, particularly for pharmaceuticals, biotechnology, medical technology companies, and clinical research organizations. Scientist.com is an inclusive research platform—with a global network exceeding 4,000 suppliers—encouragi...
Read more

Envisioning the Dual Repercussions of FDA’s Accelerated Approval Pathway

Image
Clinical trials are comprehensive research studies conducted to ensure that recently developed medical interventions, including novel drugs, surgical & other devices, and treatments/ therapies, are safe and effective for human use before commercialization. These trials provide evidence for regulatory bodies like the US Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, UK’s Medicines and Healthcare Products Regulatory Agency, and China’s National Medical Products Administration (NMPA) to ensure that a specific medical intervention is safe for the public use, begets limited adverse effects, and meets quality standards. However, it takes 10 to 15 years or even more to complete all three clinical trial phases before reaching the licensing stage. Thus, FDA introduced accelerated or expedite approvals to pace up the approval of drugs that treat severe conditions and address unmet medical needs. Before proceeding with the pros and cons of the FDA’s expe...
Read more